Tirzepatide 100mg

What is Tirzepatide (100 mg)?

Tirzepatide is a synthetic peptide used in laboratory research to investigate metabolic signaling pathways involved in energy balance and nutrient-responsive processes. Often categorized within the weight-loss and metabolic peptides research area, Tirzepatide is typically studied in models examining incretin receptor activity and subsequent cellular signaling. It is a valuable tool for receptor assays, pathway analysis, and comparative studies of metabolic peptide candidates in controlled experimental settings.

Product Specifications

• Synonyms: LY3298176, P1206, tirzepatida, tirzepatidum
• CAS Number: 2023788-19-2
• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight:48 g/mol
• Peptide Sequence:
  Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
• Purity: ≥95% (verified by HPLC and mass spectrometry)
• Packaging Format: 100 mg lyophilized powder in a sealed research-grade vial
• Storage Conditions: Store 2–8 °C (≤–20 °C long term). Protect from light.
• Intended Use: For Laboratory Research Use Only

Key Characteristics of Tirzepatide (100 mg)

• Defined research-grade peptide: Intended for controlled laboratory workflows, ensuring reproducibility in research outcomes.
• High purity: ≥95%, ideal for experiments requiring minimal background interference and maximum consistency.
• Aligned with metabolic research: Commonly used in studies investigating incretin signaling and its role in metabolic pathways.
• Versatile for assays: Suitable for receptor-binding and signaling experiments in various model systems.
• Light protection: To maintain peptide integrity, protect from light during handling.
• For research purposes only: Not intended for clinical, veterinary, or diagnostic applications.

How Tirzepatide (100 mg) Supports Research

Tirzepatide is a key tool in research focused on receptor-mediated metabolic signaling and cellular responses. It can support comparisons of pathway activation patterns, assessment of receptor-driven responses across different models, and standardization of assays in metabolic peptide studies. Its usage enables reproducible findings across experimental designs and contributes to a better understanding of incretin-related receptor biology.

Research Applications & Usage Information

• Receptor interaction studies: Evaluating receptor binding and engagement in assay systems.
• Cell signaling research: Supporting the mapping of downstream signaling pathways in experimental models.
• Metabolic pathway research: Used in studies that explore energy regulation mechanisms in biological systems.
• Comparative peptide research: Serving as a reference for comparing different peptide candidates or analogs in metabolic studies.
• Assay development: Assisting in establishing controls and benchmarks for experimental methods.
• Stability assessments: Employed in studies analyzing peptide stability under defined storage and handling conditions.

Handling and Storage Recommendations

• Minimize light exposure; follow good laboratory practices for handling to reduce contamination risk.
• Keep containers tightly closed when not in use to prevent moisture exposure.
• Ensure proper documentation and internal lot tracking for research purposes.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
2. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225. Published 2021 Nov 24. doi:10.1186/s12933-021-01412-5
3. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009